Drug Trial Radar · NCT05196035
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
219
Planned (sponsor's estimate)
Start
Mar 28, 2022
Primary completion
Apr 10, 2027
Study completion May 10, 2027
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jan 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine. The kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood pressure, also known as hypertension. Vice versa, hypertension and proteinuria can also contribute to worsening of CKD. Therefore, the treatment of CKD aims to control blood pressure and proteinuria. There are treatments available for doctors to prescribe to children with CKD and hypertension and/or proteinuria. These include "angiotensin-converting enzyme inhibitors" (ACEI) and "angiotensin receptor blockers" (ARB). Both ACEI and ARB can improve kidney function by helping the renin-angiotensin-aldosterone system (RAAS) to work normally. The RAAS is a system that works with the kidneys to control blood pressure and the balance of fluid and electrolytes in the blood. In people with CKD, the RAAS is often too active, which can stop the kidneys from working properly and cause hypertension and proteinuria. However, ACEI or ARB treatment alone does not work for all patients with CKD as they only target the angiotensin part of the renin-angiotensin-aldosterone system. The study treatment, finerenone, is expected to help control RAAS overactivation together with an ACEI or ARB. So, the researchers in this study want to learn more about whether finerenone given in addition to either an ACEI or ARB can help their kidney function. The main purpose of this study is to learn more about whether finerenone added to either ACEI or ARB can help reduce the amount of protein in the participants' urine more than a placebo. A placebo looks like a treatment but does not have any medicine in it. Participants will also continue to receive their other medications. To see how the treatment work, the doctors will take samples of the participants' urine to measure their protein levels before and during taking treatment and after their last treatment. In addition, blood samples will be taken to monitor kidney function, electrolytes and the amount of finerenone in the blood as well as for other tests. This study will include children with CKD and proteinuria aged from 6 months up to less than 18 years. The participants will take: * either finerenone or the placebo, in addition to * either ACEI or ARB, whichever they take as part of their normal treatment Two visits are required up to 104 days, to check whether a child can take part in the treatment phase of the study. If participants qualify for the treatment phase, they will then undergo treatment for about 180 days. During this time, they will visit the study site at least 7 times. During these visits, the participants will: * have their blood pressure, heart rate, temperature, height and weight measured * have blood and urine samples taken * have physical examinations * have their heart examined by an electrocardiogram and echocardiography (a sonogram of the heart) * answer questions about their medication and whether they have any adverse events , or have their parents or guardians answer * answer questions about how they are feeling, or have their parents or guardians answer * answer question about how they like the study medication, or have their parents or guardians answer The doctors will keep track of any adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The doctors will check the participants' health about 30 days after the participants take their last treatment.
Conditions
- Chronic Kidney Disease
- Proteinuria
Interventions
Finerenone (Kerendia, BAY94-8862)Drug
Finerenone in different doses, treatment duration will be 180±7 days
PlaceboDrug
Placebo to finerenone, treatment duration will be 180±7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in Urinary protein-to-creatinine ratio (UPCR) reduction from baseline to day 180+/-7Time frame: From baseline to day 180+/-7
Locations
132 sites in 32 countries. Site status is shown where the registry gives one.
Lucille Packard Children's Hospital Stanford - Pediatric Nephrology
Palo Alto, California
UC San Diego - Altman Clinical and Translational Research Institute (ACTRI) - Linda Vista Clinic
San Diego, California
Memorial Transplant Institute - Pediatric Nephrology
Hollywood, Florida
The Charlotte R. Bloomberg Children's Center Building - Nephrology
Baltimore, Maryland
Children's Mercy Hospital Kansas City - Nephrology
Kansas City, Missouri
Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension
Cincinnati, Ohio
Cleveland Clinic | Pediatric Nephrology
Cleveland, Ohio
OHSU Doernbecher Children's Hospital - Neurology
Portland, Oregon
Eccles Primary Children's Outpatient Services - Nephrology
Salt Lake City, Utah
Seattle Children's Hospital - Nephrology
Seattle, Washington
Instituto Universitario Hospital Italiano de Buenos Aires | Hospital Italiano de Buenos Aires - Neurology Department
Buenos Aires, Argentina
Hospital General de Ninos Pedro de Elizalde | Nephrology Department
Buenos Aires, Argentina
Hospital General de Ninos Ricardo Gutierrez | Pediatric Nephrology Department
Buenos Aires, Argentina
Centro de Rehabilitacion Cardiovascular | San Luis, Argentina
San Luis, Argentina
Clinica de Nefrologia, Urologia y Enfermedades Cardiovascualares | Santa Fe, Argentina
Santa Fe, Santa Fe Province, Argentina
Queensland Children's Hospital
South Brisbane, Queensland, Australia
Monash Children's Hospital
Clayton, Victoria, Australia
Royal Children's Hospital Melbourne
Parkville, Victoria, Australia
Uniklinikum Salzburg - Landeskrankenhaus
Vienna, State of Vienna, Austria
Medizinische Univ Graz | Kinder & Jugendheilkunde
Graz, Styria, Austria
Kepler Universitätsklinikum Campus IV
Innsbruck, Tyrol, Austria
AKH Wien | Kinder & Jugendheilkunde, Kindernephrologie
Vienna, Vorarlberg, Austria
CHC Montlégia - Pediatrics
Liège, Belgium
Huderf / Ukzkf
Brussels, Brussels Capital, Belgium
CU Saint-Luc/UZ St-Luc
Brussels, Brussels Capital, Belgium
UZ Gent
Ghent, East Flanders, Belgium
UZ Gasthuisberg - Pediatric Nephrology
Leuven, Flemish Brabant, Belgium
Instituto da Crianca e do Adolescente
São Paulo, Brazil
Hospital PUC-Campinas | Centro de Pesquisa Clínica Sao Lucas
São Paulo, Brazil
Santa Casa de Misericórdia de Belo Horizonte
São Paulo, Brazil
Hospital Pequeno Principe
Curitiba, Paraná, Brazil
Hosp Clínicas Facult. Med. de Ribeirão Preto / USP
Ribeirão Preto, São Paulo, Brazil
UMHAT Sveti Georgi
Plovdiv, Plovdiv Province, Bulgaria
Alberta Children's Hospital | Nephrology Clinic
Calgary, Alberta, Canada
Centre hospitalier universitaire Sainte-Justine | Cardiology
Montreal, Quebec, Canada
Všeobecná fakultní nemocnice v Praze
Prague, Prague, Czechia
Fakultní nemocnice Motol a Homolka, Pracoviště MOTOL
Prague, Prague, Czechia
Rigshospitalet - Børn og Unge
Copenhagen, Capital Region / Region Hovedstaden, Denmark
Aarhus Universitetshospital - Børn og Unge
Aarhus N, Central Denmark Region / Region Midtjylland, Denmark
Odense Universitetshospital - HC Andersen Børne og Ungehospital
Odense, Region of Southern Denmark / Region Syddanmark, Denmark
Showing 40 of 132 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.